{"commentary":{"count":67,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":27,"podcast":20,"x_thread":20},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT02863718\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"CLL12","nct_id":"NCT02863718","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=cll12-nct02863718. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"CLL12","arms":[{"description":"Watch \\& wait","label":"Watch & wait","type":"NO_INTERVENTION"},{"description":"Placebo 420mg/d","label":"Placebo 420 mg/d","type":"PLACEBO_COMPARATOR"},{"description":"Ibrutinib 420mg/d","label":"Ibrutinib 420mg/d","type":"ACTIVE_COMPARATOR"}],"collaborators":["Janssen-Cilag Ltd."],"completion_date":{"date":"2022-07-11","type":"ACTUAL"},"conditions":["Chronic Lymphocytic Leukemia"],"enrollment":{"count":515,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Ibrutinib","type":"DRUG"},{"name":"Placebo","type":"DRUG"}],"last_update":"2024-12-30","lead_sponsor":"German CLL Study Group","official_title":"A Placebo-Controlled, Double-Blind, Randomized, Multicenter, Three Arm Phase III Trial to Compare the Efficacy and Safety of Ibrutinib vs. Placebo in Previously Untreated Binet Stage A Chronic Lymphocytic Leukemia Patients With Risk of Early Disease Progression","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2019-03-07","type":"ACTUAL"},"primary_outcomes":[{"measure":"Event-free survival (EFS)","timeFrame":"randomization until progression, initiation of subsequent treatment for CLL or death by any cause, whichever occurs first, assessed for at at least 60 months"}],"references":[{"citation":"Langerbeins P, Zhang C, Robrecht S, Cramer P, Furstenau M, Al-Sawaf O, von Tresckow J, Fink AM, Kreuzer KA, Vehling-Kaiser U, Tausch E, Muller L, Eckart MJ, Schlag R, Freier W, Gaska T, Balser C, Reiser M, Stauch M, Wendtner CM, Fischer K, Stilgenbauer S, Eichhorst B, Hallek M. The CLL12 trial: ibrutinib vs placebo in treatment-naive, early-stage chronic lymphocytic leukemia. Blood. 2022 Jan 13;139(2):177-187. doi: 10.1182/blood.2021010845.","pmid":"34758069","type":"BACKGROUND"},{"citation":"Langerbeins P, Robrecht S, Nieper P, Cramer P, Furstenau M, Al-Sawaf O, Simon F, Fink AM, Kreuzer KA, Vehling-Kaiser U, Tausch E, Schneider C, Muller L, Eckart MJ, Schlag R, Freier W, Gaska T, Balser C, Reiser M, Stauch M, Zahn MO, Dorfel S, Staib P, Behlendorf T, Hensel M, Hebart H, Klaproth H, Block A, Liersch R, Hauch U, Heinrich B, Wendtner CM, Fischer K, Stilgenbauer S, Eichhorst B, Hallek M. Ibrutinib in Early-Stage Chronic Lymphocytic Leukemia: The Randomized, Placebo-Controlled, Double-Blind, Phase III CLL12 Trial. J Clin Oncol. 2025 Feb;43(4):392-402. doi: 10.1200/JCO.24.00975. Epub 2024 Nov 27.","pmid":"39602678","type":"RESULT"}],"start_date":{"date":"2014-04-30","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Ibrutinib in Previously Untreated Binet Stage A Chronic Lymphocytic Leukemia With Risk of Disease Progression","url":"https://clinicaltrials.gov/study/NCT02863718"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/cll12-nct02863718"}